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Abstract 
  
Ischemia-reperfusion (IR) injury occurs when blood supply to an organ is disrupted and then 
restored, and underlies many disorders, notably myocardial infarction and stroke. While 
reperfusion of ischemic tissue is essential for survival, it also initiates cell death through 
generation of mitochondrial reactive oxygen species (ROS). Recent work has revealed a 
novel pathway underlying ROS production at reperfusion in vivo in which the accumulation of 
succinate during ischemia and its subsequent rapid oxidation at reperfusion drives ROS 
production at complex I by reverse electron transport (RET). Pharmacologically inhibiting 
ischemic succinate accumulation, or slowing succinate metabolism at reperfusion, have 
been shown to be cardioprotective against IR injury. Here, we determined whether ischemic 
preconditioning (IPC) contributes to cardioprotection by altering succinate kinetics during IR. 
Mice were subjected to a 30-minute occlusion of the left anterior descending coronary artery 
followed by reperfusion, with or without a protective IPC protocol prior to sustained ischemia. 
We found that IPC had no effect on ischemic succinate accumulation with both control and 
IPC mice having profound increases in succinate compared to normoxia. Furthermore, after 
only 1-minute reperfusion succinate was rapidly metabolised returning to near pre-ischemic 
levels in both groups. We conclude that IPC does not affect ischemic succinate 
accumulation, or its oxidation at reperfusion.  
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Highlights  
• Succinate accumulates during cardiac ischemia and its oxidation drives ROS 
production upon reperfusion 
• IPC does not affect succinate accumulation or oxidation during cardiac IR injury 
• Changes in succinate metabolism do not contribute to IPC 
 
Introduction 
 
Ischemia-reperfusion (IR) injury occurs when a tissue is rendered ischemic, for example by a 
thrombosis, and blood flow is subsequently restored when the obstruction is removed. IR 
injury is a major factor in a range of pathologies, notably heart attack and stroke, but also in 
many other clinically important situations such as transplantation. Consequently, there has 
been considerable interest in understanding the mechanisms of IR injury and in developing 
approaches to decrease it. We recently proposed a unifying mechanism for mitochondrial 
reactive oxygen species (ROS) production and associated myocardial damage, driven by the 
accumulation and subsequent oxidation of the tricarboxylic acid (TCA) intermediate, 
succinate [1]. Ischemic preconditioning (IPC) is one of the most reproducible and robust 
forms of cardioprotection. Since its initial description by Murry et al., [2, 3], there has been 
sustained interest in unravelling the underlying mechanisms of IPC with the hope of 
pharmacologically mimicking its beneficial effects. Despite extensive investigation, our 
understanding of the precise mechanisms of IPC remains incomplete. The modulation of 
ROS production has, however, been implicated as a key mechanism in preconditioning-
mediated cardioprotection [4, 5]. We hypothesised that IPC may act by decreasing 
mitochondrial ROS production upon IR injury by either preventing the build-up of succinate 
during ischemia, or its oxidation upon reperfusion. However, while it has been reported that 
IPC has no effect on the accumulation of succinate during ischemia in ex vivo models [6, 7], 
no work has been done on the effect of IPC on succinate using in vivo models of IR injury. 
To address this outstanding question, we measured succinate levels in an in vivo model of 
IPC. We found that IPC-mediated cardioprotection of the mouse myocardium in vivo was 
independent of any changes in either succinate accumulation or oxidation.  
 
Results & Discussion 
 
Ischemic succinate is rapidly oxidised at reperfusion within minutes  
 
To assess the impact of IPC on myocardial succinate kinetics, we first established, a 
detailed time-course of the changes in succinate abundance during IR injury in vivo. In 
previous work by our lab demonstrated that succinate returns to near baseline levels 5 min 
after reperfusion in an in vivo mouse model of LAD occlusion [1]. We set out to increase the 
time resolution of the changes in succinate levels by isolating heart tissue from within the 
ischemic risk zone at earlier time-points following reperfusion. Metabolomic analysis 
revealed that the accumulated succinate decreased  to pre-ischemic levels after 2 minutes of 
reperfusion. Interestingly, after 1 minute of reperfusion, ischemic succinate had fallen by 
85%, to 1.5-fold, versus normoxic controls (Fig. 1). The fate of ischemic succinate following 
reperfusion is disputed with some arguing that post-ischemic succinate is released from the 
cell instead of being actively oxidised by mitochondrial complex II into fumarate [6]. Analysis 
of blood samples in patients with acute ST-elevated myocardial infarction indeed show that 
succinate is, in part, released from the ischemic myocardium into the blood following primary 
percutaneous coronary intervention [9]. Recent work, however, also supports succinate 
metabolism at reperfusion, with the rapid decline in succinate being slowed upon addition of 
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the complex II inhibitor, malonate [8]. Thus upon reperfusion the accumulated succinate has 
two fates: oxidation by SDH and release from the cell.     
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Succinate rapidly declines in reperfused ischemic myocardium. Mice were subjected 
to 30 min ischemia, 30 min ischemia plus 1, 2 or 5 min reperfusion or a normoxic time-matched 
procedure. Data is expressed as fold change relative to normoxic control (n=3-6). *p<0.05, ***p<0.001 
vs normoxia (time-point zero) (one-way ANOVA with Tukey’s post-hoc analysis). Mean ± SEM (n=3-
5).  
 
Cardioprotection mediated by ischemic preconditioning is not due to changes in 
succinate accumulation or oxidation during IR injury 
 
To assess the impact of ischemic preconditioning on succinate kinetics during IR injury we 
utilized the established protocol of three sets of 5-minute ischemia and 5-minute of 
reperfusion followed by left anterior descending artery (LAD) ligation [10]. Preconditioned 
hearts exhibited significantly smaller infarcts compared to controls after 2 hours of 
reperfusion in vivo, with infarct size reducing from 34.2 ± 2.0% to 19.4 ± 3.6% of the risk 
zone, respectively (Fig. 2A). We first hypothesised that the mechanism by which IPC may 
affect mitochondrial ROS production was through disruption of succinate accumulation 
during ischemia. To investigate this hypothesis, we assessed succinate kinetics during IR 
injury, and in conjunction with IPC. IPC had no effect on ischemic succinate accumulation 
with both control and IPC mice exhibiting increases in succinate of 2.6- and 2.5-fold 
compared to normoxia, respectively (Fig. 2B). However, despite succinate accumulating to 
the same extent during ischemia, IPC may act to slow the oxidation of succinate upon 
reperfusion thereby decreasing the proton motive force for reverse electron transport (RET) 
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at complex I. IPC, however, had no effect on succinate metabolism at reperfusion, with 
succinate returning to near comparable levels in both IPC and control mice after 1 minute of 
reperfusion (Fig. 2B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The effect of IPC on metabolite abundance during IR injury in the in vivo mouse 
heart.  A) Preconditioning reduced infarct size in vivo. Representative cross-sections from mouse 
hearts after myocardial infarction ± IPC are shown. Infarcted tissue is white, the area at risk is red, 
and non-risk tissue is dark blue (n=6). **p<0.01 (two-tailed Student’s t-test). B) Metabolite abundance 
following 30 min ischemia ± IPC, and following 1 min reperfusion ± IPC. Data is expressed as fold 
change relative to normoxic control (n=4-6). ***p<0.001 vs normoxia (one-way ANOVA with Tukey’s 
post-hoc analysis). Mean ± SEM.  
 
IPC had no significant effect on other TCA cycle intermediates measured during ischemia or 
immediately upon reperfusion (Fig. 2B). This result suggests that succinate kinetics are 
unaffected by IPC. However, it should be noted that while no significant change in 
reperfusion-induced succinate levels was detected following IPC, we acknowledge the 
limitations of our tissue preservation and analytic methods, as they may be insufficiently 
sensitive to either detect minute changes in such a dynamic metabolite pool at the time-
points investigated, or distinguish intracellular vs interstitial succinate accumulation.  
 
While the formation and metabolism of ischemic succinate is central to the generation of 
ROS burst upon reperfusion, other mechanisms downstream of succinate could account for 
B 
the ROS-attenuating effect of IPC. Indeed, any manipulation of the RET pathway could 
potentially influence the end outcome of ROS production, be that preventing the rapid re-
activation of complex I, or reducing the driving hyperpolarisation of the mitochondrial 
membrane potential. Interestingly, IPC has also been demonstrated to induce S-nitrosation 
of complex I, a modification shown to inhibit complex I-mediated ROS production [13, 14]. 
During ischemia the ATP/ADP ratio progressively decreases, and accumulated AMP is 
further metabolised to hypoxanthine and xanthine. Upon reperfusion, ATP synthesis is 
compromised due to a delay in the repletion of adenine nucleotides [12]. Due to the influx of 
electrons from oxidised succinate the Coenzyme Q (CoQ) pool is maintained in a highly 
reduced state, which forces RET, resulting in a ROS burst. In one of the original descriptions 
of IPC, Murry et al. made the interesting observation that IPC slowed the rate of ATP decline 
during ischemia suggesting a reduction in ATP utilisation [3]. This effect was similarly 
observed by Kaplan et al. in which they demonstrated IPC preserved end-ischemic ATP in 
isolated perfused rat hearts [11]. The subsequent preservation of ADP during ischemia could 
enhance oxidative phosphorylation upon reperfusion, thereby decreasing the proton motive 
force and oxidizing the CoQ pool at reperfusion, ultimately reducing RET and subsequent 
ROS production.  
 
Conclusion  
 
We conclude that IPC has no effect on succinate kinetics during cardiac IR injury. The 
accumulation and metabolism of ischemic succinate seems to be a promising  therapeutic 
target when targeting IR injury. It is, however, not the only target or mechanistic component 
by which IPC could act to disrupt RET-mediated ROS production upon reperfusion in vivo. 
 
Methods 
 
In vivo experiments 
This research was conducted in accordance with the Animals (Scientific Procedures) Act 
1986 Amendment Regulations 2012 following ethical review by the University of Cambridge 
Animal Welfare and Ethical Review Body (AWERB) under Project Licence numbers 80/2374, 
and 70/8238. 
 
An open-chest, in situ left anterior descending (LAD) coronary artery infarct model was used 
as previously described [15]. Briefly, C57BL/6 male mice (8-10 weeks of age; Charles River 
Laboratories, UK) were anesthetized with sodium pentobarbital (70 mgykg-1 body weight 
intraperitoneally), intubated endotracheally and ventilated with 3 cm H2O positive-end 
expiratory pressure. Ventilation frequency was maintained at 110 breathsymin-1 with tidal 
volume between 125 and 150 μl. A thoracotomy was performed and the pericardium 
stripped to expose the heart. The LAD was surrounded by a 7-0 Prolene suture, which was 
then passed through a small plastic tube. Ischemia was induced by tightening the tubing 
against the heart surface to occlude blood flow. Mice in the IPC group were subjected to 3 x 
5 min of ischemia/reperfusion episodes followed by an intervening 10 min period prior to the 
induction of prolonged ischemia. Infarct size was assessed following 30 min ischemia, 120 
min reperfusion using 2% triphenyltetrazolium chloride staining, and is expressed as a 
percentage of the risk zone. 
For metabolomic analyses myocardial tissue was removed from the ischemic risk 
zone at the end of ischemia, and following 1, 2 and 5 min reperfusion, rapidly snap-frozen in 
liquid nitrogen and stored at -80°C until analysis. Data was normalised to tissue isolated 
from normoxic time-matched animals.  
 
Metabolomic analyses 
Equal amounts of wet weight murine tissue were lysed in 250 ml extraction solution (30% 
acetonitrile, 50% methanol and 20% water) per 10 mg tissue in a Bullet Blender (Next 
Advance) following the manufacturer’s instructions. The suspension was immediately 
centrifuged (16,000g, 15 min at 4°C) and the supernatant analysed by liquid 
chromatography-mass spectrometry. Sample extracts were run twice on a liquid 
chromatography system fitted with a Sequant ZIC-HILIC column (5 µm, 4.6 x 150 mm) and 
afterwards with a Sequant ZIC-pHILIC column (5 µm, 2.1 x 150 mm), with the corresponding 
guard columns (both 2.1 x 20 mm, 5 µm) (all from Merck), and according to previously 
described gradient elution methods [1]. The mass spectrometer (Thermo Q Exactive) was 
operated in full scan mode with polarity switching. Samples were randomized to avoid bias 
due to machine drift and the operator was blinded to the sample key. Spectra were analysed 
using Xcalibur Quan Browser software (Thermo Fisher Scientific) by referencing to an 
internal library of compounds.  
 
Statistics and experimental design 
 
Data were expressed as mean ± SEM, and p values calculated using a two-tailed Student’s 
t-test for pairwise comparisons, and one-way analysis of variance (ANOVA) followed by 
Tukey’s test for multiple comparisons. Differences were considered significant if p<0.05. 
Histological analysis of infarct size was performed blinded by an independent researcher.   
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